Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming?
QL Zeng, ZQ Li, HX Liang, GH Xu, CX Li… - Journal of …, 2016 - journal-of-hepatology.eu
As a terminator of hepatitis C virus (HCV) infection, sofosbuvirbased direct-acting antiviral
agent (DAA) regimens have achieved great success in the eradication of HCV in patients
with hepatitis C and related end stage liver diseases [1, 2]. Recently, we read with interest
the studies by Reig et al.[3] and Kozbial et al.[4] on the surprisingly high incidence of
hepatocellular carcinoma (HCC) recurrence and occurrence in patients with advanced liver
diseases during interferon (IFN)-free therapy and after sustained virologic response (SVR) …
agent (DAA) regimens have achieved great success in the eradication of HCV in patients
with hepatitis C and related end stage liver diseases [1, 2]. Recently, we read with interest
the studies by Reig et al.[3] and Kozbial et al.[4] on the surprisingly high incidence of
hepatocellular carcinoma (HCC) recurrence and occurrence in patients with advanced liver
diseases during interferon (IFN)-free therapy and after sustained virologic response (SVR) …